Newsroom / Industry / Industry / Lead Generation Strategies and Technologies in Drug Development

Lead Generation Strategies and Technologies in Drug Development

Decrease in Approval of NME and Increase in R&D Cost are the Major Drivers for Accelerating Lead Generation Process
London, London, United Kingdom ( 02/06/2011
Over time, the FDA; the regulatory agency for the US pharmaceutical market, has adopted a
progressively stricter regime for drug approval, resulting in a significant decrease in the number of
new molecular entities (NMEs) approved over the past decade.

The FDA has been continuously criticized for its overly strict standards surrounding drug approvals.
Following the cases of Vioxx, Exubera (insulin human [rDNA origin]) as well as product recalls of
“Made in China” drugs, the agency has been more cautious in analyzing the risks and benefits of
drugs before approving them.

In 1996 the number of NMEs approved was 53. This declined to just 17 in 2002. In 2008, the
number of NMEs approved was 21, reflecting a better picture than in 2007 when only 16 drugs, the
lowest number of the last 13 years, were approved.

For Sample Pages, please click or add the below link to your browser:

This reduction in NME approvals reflects the need to accelerate the lead generation process by
which potential lead molecules reach trials. The faster the molecule enters trials, the faster the
results of its efficacy can be seen and applied.

The in silico method of drug discovery is preferred over traditional laboratory methods due to its
ability to process large amounts of data in comparatively less time. This preference is also based
on its low cost and the growing computational resources of in silico methods.

With modern day drug discovery encompassing large quantities of compounds and reducing the
time period needed to examine them, the assistance of computer technology is inevitable. Thus,
the need for the storage, management and analysis of large quantities of compounds has given
rise to CADD as a tool to accelerate the modern day drug discovery process. CADD utilizes
computational chemistry to discover and enhance optimization of the study drugs and related
biologically active molecules. The objective is to predict the binding strength of given molecules in
relation to their target.

GBI Research, the leading business intelligence provider, has released its latest research, “Lead
Generation Strategies and Technologies in Drug Development - Emerging Techniques Such
as Antisense Technology Will Allow Innovators to Minimize Costs”. It provides key data,
information and analysis on lead generation and optimization technologies implemented by
pharmaceutical companies or the contract research organizations. The report provides information
on the emerging technologies and the strategies in lead generation along with the need for
accelerating the lead generation process. The report also analyses the economic impact of
compound attrition at various stages of the lead generation process. It also reviews the outsourcing
landscape to the contract research organizations. It is built using data and information sourced from
proprietary databases, primary and secondary research and in house analysis by GBI Research’s
team of industry experts.

For further details, please click or add the below link to your browser:

Visit our report store:

For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782


GBI Research is a global market intelligence services company providing information research and analysis products and services.


Rajesh Gunnam

John Carpenter House, John Carpenter Street
Zipcode : EC4Y 0AN